(Q28286173)

English

Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals

scientific article

In more languages

Statements

scholarly article

0 references

Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals (English)

0 references

Christophe Lallemand

6

object named as

Christophe Lallemand

0 references

1

object named as

Odile Launay

0 references

author name string

Sophie Grabar

2

0 references

Frédéric Bloch

3

0 references

Corinne Desaint

4

0 references

David Jegou

5

0 references

Robert Erickson

7

0 references

Pierre Lebon

8

0 references

Michael G Tovey

9

0 references

language of work or name

0 references

publication date

29 July 2008

0 references

0 references

26

0 references

32

0 references

4073-9

0 references

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Effectiveness of influenza vaccine in the community-dwelling elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Dendritic cells: translating innate to adaptive immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Type I interferons promote cross-priming: more functions for old cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Adjuvants and their signaling pathways: beyond TLRs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Oromucosal interferon therapy: marked antiviral and antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Absence of Biological Effects of Orally Administered Interferon-βser

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Induction of tolerance to recombinant therapeutic proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Cellular responses in chickens treated with IFN-alpha orally or inoculated with recombinant Marek's disease virus expressing IFN-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Interferon action on avian viruses. I. Oral administration of chicken interferon-alpha ameliorates Newcastle disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Protection from lethal influenza virus challenge by oral type 1 interferon.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Ingested (oral) IFN-alpha represses TNF-alpha mRNA in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Oral use of interferon-alpha stimulates ISG-15 transcription and production by human buccal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Efficacy of Low-Dose Oral Use of Type I Interferon in Cytomegalovirus Infections In Vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Low-Dose Orally Administered Type I Interferon Reduces Splenic B Cell Numbers in Mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Low-dose oral use of interferon inhibits virally induced myocarditis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Autoimmunity is a type I interferon-deficiency syndrome corrected by ingested type I IFN via the GALT system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Host genotype influences immunomodulation by interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.035

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.05.035

0 references

release_tiaabzdlffbmdacbg5s4tc2jam

1 reference

https://api.fatcat.wiki/v0/release/tiaabzdlffbmdacbg5s4tc2jam

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28286173&oldid=1836740517"